Publication | Open Access

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Metastatic Breast CancerOncologyBreast OncologyMedicineAbiraterone AcetateTriple-negative Androgen ReceptorBreast CancerPharmacotherapyCancer TreatmentPharmacologyEndocrine-related Cancer